Efficacy and safety of liposome‐encapsulated 4‐n‐butylresorcinol 0.1% cream for the treatment of melasma: A randomized controlled split‐face trial
- 25 March 2010
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 37 (4), 311-315
- https://doi.org/10.1111/j.1346-8138.2010.00787.x
Abstract
Melasma is an acquired pigmentary disorder that most commonly occurs in women of child-bearing age. Melasma is therapeutically challenging, and most commercially available hypopigmenting agents include tyrosinase inhibitors, which regulate the rate-limiting step of melanogenesis. 4-n-Butylresorcinol has received considerable attention as a novel hypopigmenting agent in the last 15 years because it has an inhibitory effect against tyrosinase and tyrosinase-related protein-1. However, the hypopigmenting effect of 4-n-butylresorcinol in human subjects has only been shown in a few studies. Liposome encapsulation is known to improve stabilization and enhance penetration of the product. Therefore, this study was conducted to evaluate the hypopigmenting efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream in patients with melasma. This was a randomized, double-blind, vehicle-controlled and split-face comparison study. Twenty-three patients with a clinical diagnosis of melasma were included. 4-n-Butylresorcinol 0.1% cream or vehicle was applied to each side of the face twice daily for 8 weeks. Clinical and photographic evaluations, Mexameter measurements and assessment of patient satisfaction and side-effects were performed at baseline, 4 and 8 weeks. All subjects completed the study. Mexameter measurements demonstrated that the melanin index of the 4-n-butylresorcinol-treated side showed a significant decrease when compared with the vehicle-treated side after 8 weeks (P = 0.043). No adverse reactions were observed throughout the study. Subjectively, 4-n-butylresorcinol was considered to be efficacious in more than 60% of the patients after 8 weeks of treatment. In conclusion, liposome-encapsulated 4-n-butylresorcinol 0.1% cream was well tolerated and showed significant higher efficacy than vehicle alone for the treatment of melasma.Keywords
This publication has 17 references indexed in Scilit:
- Liposomes in dermatology todayJournal of the European Academy of Dermatology and Venereology, 2009
- Clinical effects of undershirts coated with borage oil on children with atopic dermatitis: A double‐blind, placebo‐controlled clinical trialThe Journal of Dermatology, 2007
- Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trialBritish Journal of Dermatology, 2007
- Novel Drug Delivery Systems: Potential in Improving Topical Delivery of Antiacne AgentsSkin Pharmacology and Physiology, 2005
- Inhibition of Tyrosinase by Flavonoids, Stilbenes and Related 4-Substituted Resorcinols: Structure-Activity InvestigationsPlanta Medica, 2000
- Peeling agents: toxicological and allergological aspectsJournal of the European Academy of Dermatology and Venereology, 1999
- Efficacy of Rusinol (4-n-butylresorcinol) on chloasma.The Nishinihon Journal of Dermatology, 1999
- 153 The inhibitory effects of 4-N-butyl-resorcinol on melanogenesisJournal of Dermatological Science, 1995
- Topical evening primrose oil as treatment for atopic eczemaJournal of Dermatological Treatment, 1990